Access Pharmaceuticals Inc. (ACCP.OB) Inks Marketing and Distribution Agreement for its FDA-approved Mucositis Treatment to Alleviate Cancer Therapy Side-effects
Access Pharmaceuticals Inc. develops and commercializes proprietary products for the treatment and care of cancer patients. The company today announced an agreement with commercial manufacturer Accupac Inc. to produce and distribute Access’ FDA-approved MuGard in the North American market. MuGard is a mucoadhesive oral wound rinse for patients in radiation and chemotherapy that often-time develop mucositis, or the inflammation of mucous membranes along the lining of the digestive track, including the mouth. The company says the market for treating oral mucositis is estimated at $5 billion worldwide. "Access is moving forward with the development of MuGard in North America," Jeffrey…